Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S

Core Points - Novo Nordisk A/S held an Extraordinary General Meeting to elect new members of the Board of Directors [1][2] - Lars Rebien Sørensen was elected as the new chair of the Board of Directors, with Cees de Jong as vice chair [5][6] - The Board of Directors aims to support the CEO in transformation plans and engage with minority shareholders [3] Board Composition - The new Board of Directors includes Lars Rebien Sørensen (chair), Cees de Jong (vice chair), and other members such as Britt Meelby Jensen and Stephan Engels [5][6] - The Board is responsible for various committees, including the Audit Committee and the Remuneration Committee [6] Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, focusing on chronic diseases, particularly diabetes [4] - The company employs approximately 78,500 people across 80 countries and markets its products in around 170 countries [4]